Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review
Health Economics Review Open Access 19 June 2024
-
The estimated annual financial impact of gene therapy in the United States
Gene Therapy Open Access 08 November 2023
-
Scaffold-free cell-based tissue engineering therapies: advances, shortfalls and forecast
npj Regenerative Medicine Open Access 29 March 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Wilson, J.M. Genet. Eng. News 33, 62 (2013).
Kohn, D.B., Pai, S.Y. & Sadelain, M. Biol. Blood Marrow Transplant. 19, S64–S69 (2013).
Xiao, P.J., Lentz, T.B. & Samulski, R.J. Ther. Deliv. 3, 835–856 (2012).
Maguire, A.M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).
Nathwani, A.C. et al. N. Engl. J. Med. 365, 2357–2365 (2011).
Buchlis, G. et al. Blood 119, 3038–3041 (2012).
Bryant, L.M. et al. Hum. Gene Ther. Clin. Dev. 24, 55–64 (2013).
Anonymous. Delivering gene therapy to patients. Presented at the Jefferies 2014 Global Healthcare Conference, June 2–5, 2014, New York.
Kesselheim, A.S. Milbank Q. 89, 450–502 (2011).
Nathan, D.G. & Orkin, S.H. Genome Med. 1, 114 (2009).
Berndt, E.R. & Hurvitz, J.A. Health Aff. (Millwood) 24, 653–665 (2005).
Kremer, M. in Innovation Policy and the Economy (eds. Jaffe, A., Lerner, J. & Stern, S.) (MIT Press, Boston, 2001).
National Library of Medicine. Genetics Home Reference (National Library of Medicine, 2014).
Brennan T. & Shrank W. J. Am. Med. Assoc. 312, 593–594 (2014).
Bordonaro, G. Hartfordbusiness.com, vol. 2014 Cigna, Merck ink pay-for-performance deal. (The Hartford Business Journal, 2009). <http://www.hartfordbusiness.com/article/20090525/PRINTEDITION/305259968/cigna-merck-ink-pay-for-performance-deal>
Gostin, L.O., Hyman, D., Jacobson, P.D. & Studdert, D. Law and the Health System: Casebook Series (Foundation Press, 2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.W. is an advisor to and a founder of ReGenX Biosciences and Dimension Therapeutics; he also holds equity in and receives a grant from these companies. In addition, he is an inventor on patents licensed to various biopharmaceutical companies, including affiliates of ReGenX Holdings, and consults on an ad hoc basis for several biopharmaceutical companies. He is an inventor on the vector used in the Glybera product. T.A.B. is employed by and holds stock in CVS Caremark.
Rights and permissions
About this article
Cite this article
Brennan, T., Wilson, J. The special case of gene therapy pricing. Nat Biotechnol 32, 874–876 (2014). https://doi.org/10.1038/nbt.3003
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt.3003
This article is cited by
-
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review
Health Economics Review (2024)
-
The estimated annual financial impact of gene therapy in the United States
Gene Therapy (2023)
-
Scaffold-free cell-based tissue engineering therapies: advances, shortfalls and forecast
npj Regenerative Medicine (2021)
-
Beating the organ clock
Nature Biotechnology (2018)
-
Challenges in the gene therapy commercial ecosystem
Nature Biotechnology (2017)
